| Authors: |
Tanus T; Tonny Tanus, MD, is Director, Kern Allergy Medical Clinic Inc, Bakersfield, California, and Assistant Clinical Professor, David Geffen School of Medicine, University of California, Los Angeles. Nicole E. Scangarella-Oman, MS, is an Investigator; Marybeth Dalessandro, BS, is Manager, Clinical Development; Gang Li, PhD, is Manager, Statistics; John J. Breton, MCM, is Manager, Clinical Development; and John F. Tomayko, MD, is Senior Director, all in the Department of Infectious Diseases Medicines Discovery and Development, GlaxoSmithKline, Collegeville, Pennsylvania. The authors disclose they will discuss off-label uses of retapamulin 1% (Altabax, Altargo). Dr Tanus has disclosed that he is/was a recipient of grant/research funding from Stiefel/GlaxoSmithKline, Amgen, and Genentech; he is a recipient of grant/research funding from Teva Pharmaceuticals; and he was a member of the speakers' bureau for Astra Zeneca. The coauthors have disclosed they are employees of GlaxoSmithKline. Ms Scangarella-Oman, Ms Dalessandro, Mr Breton, and Dr Tomayko have disclosed they are stock shareholders of GlaxoSmithKline. The authors disclose that the study was supported by funding from GlaxoSmithKline., Scangarella-Oman NE, Dalessandro M, Li G, Breton JJ, Tomayko JF |
